Validation of a protein biomarker test for predicting renal decline in type 2 diabetes: The Fremantle Diabetes Study Phase II.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Pub. Co Country of Publication: United States NLM ID: 9204583 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-460X (Electronic) Linking ISSN: 10568727 NLM ISO Abbreviation: J Diabetes Complications Subsets: MEDLINE
    • Publication Information:
      Original Publication: New York, NY : Elsevier Science Pub. Co., c1992-
    • Subject Terms:
      Biomarkers/*blood ; Diabetes Mellitus, Type 2/*complications ; Diabetes Mellitus, Type 2/*diagnosis ; Diabetic Nephropathies/*diagnosis; Adult ; Aged ; Aged, 80 and over ; Biomarkers/analysis ; Cohort Studies ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/pathology ; Diabetic Nephropathies/blood ; Diabetic Nephropathies/pathology ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Risk Factors
    • Abstract:
      Aims: To validate the prognostic utility of a novel plasma biomarker panel, PromarkerD, for predicting renal decline in an independent cohort of people with type 2 diabetes.
      Methods: Models for predicting rapid estimated glomerular filtration rate (eGFR) decline defined as i) incident diabetic kidney disease (DKD), ii) eGFR decline ≥30% over four years, and iii) annual eGFR decline ≥5 mL/min/1.73 m 2 were applied to 447 participants from the longitudinal observational Fremantle Diabetes Study Phase II. Model performance was assessed using discrimination and calibration.
      Results: During 4.2 ± 0.3 years of follow-up, 5-10% of participants experienced a rapid decline in eGFR. A consensus model comprising apolipoprotein A-IV (apoA4), CD5 antigen-like (CD5L), insulin-like growth factor-binding protein 3 (IGFBP3), age, serum HDL-cholesterol and eGFR showed the best performance for predicting incident DKD (AUC = 0.88 (95% CI 0.84-0.93)); calibration Chi-squared = 5.6, P = 0.78). At the optimal score cut-off, this model provided 86% sensitivity, 78% specificity, 30% positive predictive value and 98% negative predictive value for four-year risk of developing DKD.
      Conclusions: The combination of readily available clinical and laboratory features and the PromarkerD biomarkers (apoA4, CD5L, IGFBP3) proved an accurate prognostic test for future renal decline in an independent validation cohort of people with type 2 diabetes.
      (Copyright © 2019 Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Biomarkers; Diabetic kidney disease; Diabetic nephropathy; Prognostic test; Type 2 diabetes
    • Accession Number:
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20191101 Date Completed: 20210406 Latest Revision: 20210406
    • Publication Date:
      20240628
    • Accession Number:
      10.1016/j.jdiacomp.2019.07.003
    • Accession Number:
      31669066